Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CHAIRPERSON & CEO

PRESIDENT AND COO

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unme...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-09	Premium	acquired	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-09	Premium	sold	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-08	Premium	sold	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-08	Premium	acquired	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-07	Premium	sold	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-07	Premium	acquired	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-06	Premium	acquired	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-06	Premium	acquired	Premium	Premium	Premium	PRESIDENT AND COO
2024-05-06	Premium	back to issuer	Premium	Premium	Premium	PRESIDENT AND COO
2024-05-06	Premium	sold	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-03	Premium	acquired	Premium	Premium	Premium	-
2024-05-03	Premium	sold	Premium	Premium	Premium	-
2024-05-03	Premium	sold	Premium	Premium	Premium	-
2024-05-03	Premium	acquired	Premium	Premium	Premium	-
2024-05-03	Premium	sold	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-03	Premium	acquired	Premium	Premium	Premium	-
2024-05-03	Premium	sold	Premium	Premium	Premium	-
2024-05-03	Premium	acquired	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-02	Premium	acquired	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-02	Premium	sold	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-01	Premium	sold	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-05-01	Premium	acquired	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-04-30	Premium	acquired	Premium	Premium	Premium	CHAIRPERSON & CEO
2024-04-30	Premium	sold	Premium	Premium	Premium	CHAIRPERSON & CEO

UTHR - United Therapeutics Corp Stock Price, Fair Value and News

Latest Insider Trading transactions for UTHR